China 
Africa 
Explore chapters and articles related to this topic
Nanoparticle Synthesis and Administration Routes for Antiviral Uses
Published in Devarajan Thangadurai, Saher Islam, Charles Oluwaseun Adetunji, Viral and Antiviral Nanomaterials, 2022
João Augusto Oshiro-Júnior, Kammila Martins Nicolau Costa, Isadora Frigieri, Bruna Galdorfini Chiari-Andréo
In the same study, the authors cited that PLGA nanoparticles coated with bovine serum albumin were considered a promising delivery system. In addition, tenofovir, used for the treatment of chronic hepatitis B (HBV) and also for the treatment and prevention of HIV, was dispersed in lipid nanoparticles in order to establish a long-term release of the drug and improve bioavailability (Grande et al. 2019).
The roadmap towards cure of chronic hepatitis B virus infection
Published in Journal of the Royal Society of New Zealand, 2022
New Zealand was the second country to introduce universal neonatal vaccination (in 1988 less than 1 year after Taiwan), including birth dose in all infants of mothers who are HBsAg+. Cases of vertical transmission are now restricted to a few sporadic cases in infants born to HBsAg+/HBeAg+ mothers with very high levels of viraemia (defined as HBV DNA >6 log IU/ml), where transplacental HBV transmission occurs late in pregnancy rather than at birth. Although administration of the first (‘birth-dose’) vaccine dose within 12 h post-partum with or without hepatitis B immunoglobulin (HBIG) will reduce this risk, the best prevention is reduction of maternal viraemia during the 3rd trimester of pregnancy with prophylactic tenofovir disoproxil (TDF).
Intramolecular π-stacks in mixed-ligand copper(II) complexes formed by heteroaromatic amines and antivirally active acyclic nucleotide analogs carrying a hydroxy-2-(phosphonomethoxy)propyl residue‡
Published in Journal of Coordination Chemistry, 2018
Claudia A. Blindauer, Rolf Griesser, Antonín Holý, Bert P. Operschall, Astrid Sigel, Bin Song, Helmut Sigel
Perhaps the most significant of all ANPs is, however, Tenofovir, which differs from HPMPA by the replacement of a HO–CH2– by a CH3– group (cf with Figure 1). Tenofovir has substantially contributed to turning AIDS into a chronic condition rather than a death sentence [23]. Among the highly effective treatment regimens are currently 14 different Tenofovir-based medicines approved by EMA [24], and a similar number are FDA-approved [25]. A further derivative, bis(hexadecyloxypropyl)-Tenofovir (Tenofovir exalidex), is currently in Phase 2a clinical trials for treatment of hepatitis B infection [26].